Clin Exp Rheumatol. 2023 doi: 10.55563/clinexprheumatol/vezf95
The presence of dactylitis was associated with a higher disease burden in patients with PsA compared with those without dactylitis at baseline. The aim of this study was to evaluate the efficacy of secukinumab in patients with dactylitis at baseline over 2 years.
This analysis extends the evidence for the early and sustained efficacy of secukinumab on dactylitis. This was irrespective of severity and comprehensive efficacy across other PsA domains, low radiographic progression, improvement of function, and HRQoL to the same extent as patients without dactylitis.